NCT00066157View on ClinicalTrials.gov

Alzheimer's Disease: Therapeutic Potential of Estrogen

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Alzheimer Disease
Interventions
DRUG

Transdermal estradiol

50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months

DRUG

Medroxyprogesterone

2.5mg tablet daily for 12 months

DRUG

Placebo Patch

Transdermal placebo patch, changed every 3 days, for 12 months

DRUG

Placebo

Placebo tablet daily for 12 months

Trial Locations (1)

53705

University of Wisconsin Memory Research Program, Madison

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT00066157 - Alzheimer's Disease: Therapeutic Potential of Estrogen | Biotech Hunter | Biotech Hunter